Publication: Comparison of prevention of NSAID-induced gastrointestinal complications by rebamipide and misoprostol: A randomized, multicenter, controlled trial - STORM study
1
Issued Date
2007-03-01
Resource Type
ISSN
09120009
Other identifier(s)
2-s2.0-34247258850
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Journal of Clinical Biochemistry and Nutrition. Vol.40, No.2 (2007), 148-155
Suggested Citation
Soo Heon Park, Chul Soo Cho, Oh Young Lee, Jae Bum Jun, San Ren Lin, Li Ya Zhou, Yao Zong Yuan, Zhao Shen Li, Xiao Hua Hou, Hong Chuan Zhao, Udom Kachintorn, Chomsri Kositchaiwat, Comson Lertkupinit Comparison of prevention of NSAID-induced gastrointestinal complications by rebamipide and misoprostol: A randomized, multicenter, controlled trial - STORM study. Journal of Clinical Biochemistry and Nutrition. Vol.40, No.2 (2007), 148-155. doi:10.3164/jcbn.40.148 Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/24244
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Comparison of prevention of NSAID-induced gastrointestinal complications by rebamipide and misoprostol: A randomized, multicenter, controlled trial - STORM study
Abstract
Nonsteroidal anti-inflammatory drugs (NSAIDs) have gastrointestinal side effects such as dyspepsia, peptic ulcer, hemorrhage, and perforation. Misoprostol and PPIs have been used to prevent NSAID-induced gastroduodenal injury. Rebamipide increases gastric mucus and stimulates the production of endogenous prostaglandins. The prophylactic effect of rebamipide on NSAID-induced gastrointestinal complications is unknown. The aim of this study was to compare NSAID-induced gastrointestinal complications in rebamipide- and misoprostol-treated groups. Patients were randomized to two groups and took a conventional NSAID plus rebamipide or misoprostol for 12 weeks. Gastric mucosal damage was evaluated by endoscopy at screening and the end of the study. The prevalences of active gastric ulcer were 7/176 (3.9%) in the rebamipide group and 3/156 (1.9%) in the misoprostol group. The prevalences of peptic ulcer were 8/176 (4.5%) in the rebamipide group and 7/156 (4.4%) in the misoprostol group. The cumulative incidences of peptic ulcer in the high-risk subgroup were 6/151 (4.0%) for rebamipide and 6/154 (3.9%) for misoprostol. In conclusion, rebamipide prevented NSAID-induced peptic ulcer as effectively as misoprostol in patients on long-term NSAID therapy. Rebamipide may be a useful therapeutic option for the prevention of NSAID-induced gastrointestinal ulcer because of its therapeutic effect and safety.